Genmin Lu

机构：AstraZeneca (Australia), Alexion Pharma (Switzerland) · ORCID：0000-0002-1518-4434

发表论文 60 篇 · 总被引 4800 次 · h-index 22

代表论文

• Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors (2019 · New England Journal of Medicine · 被引 955)
• Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors (2018 · Blood Advances · 被引 64)
• A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers (2020 · Blood Advances · 被引 42)
• Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban (2022 · Thrombosis and Haemostasis · 被引 38)
• Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation (2020 · Research and Practice in Thrombosis and Haemostasis · 被引 38)
• Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model (2018 · PLoS ONE · 被引 33)